Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke.

COVID-19 LDL cholesterol endothelial dysfunction familial hypercholesterolemia statins stroke

Journal

eNeurologicalSci
ISSN: 2405-6502
Titre abrégé: eNeurologicalSci
Pays: Netherlands
ID NLM: 101667077

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 21 02 2021
revised: 18 04 2021
accepted: 25 04 2021
entrez: 3 5 2021
pubmed: 4 5 2021
medline: 4 5 2021
Statut: ppublish

Résumé

There is a continuing need for research about the underlying mechanisms behind ischemic strokes in COVID-19 patients. Pre-existing endothelial dysfunction, especially if it is accompanied by a viral infection of the endothelial cells may present an important mechanism behind the immunothrombotic/thromboembolic complications of the COVID-19 illness. Here we emphasize that pharmacotherapy with statins could partly counteract such pathophysiological scenarios. Accordingly, using familial hypercholesterolemia (FH) as a pertinent example of a lifelong endothelial dysfunction, we aim to make the clinicians and consulting neurologists aware of statins as a possible adjuvant therapy in the context of an increased risk of ischemic stroke in patients with COVID-19. Based on recent clinical evidence, there is a need to encourage clinicians and consulting neurologists to continue or initiate effective statin treatment to prevent an ischemic stroke, particularly when they encounter a hypercholesterolemic COVID-19 patient with FH.

Identifiants

pubmed: 33937536
doi: 10.1016/j.ensci.2021.100344
pii: S2405-6502(21)00036-8
pmc: PMC8078044
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100344

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

AV, MK none. PTK has received lecture honoraria and/or travel fees from Amgen, Novartis, Raisio Group, and Sanofi.

Références

Stroke. 2005 Jul;36(7):1572-4
pubmed: 15933262
Metabolism. 2013 Jun;62(6):820-7
pubmed: 23357531
Eur Heart J. 2017 Dec 21;38(48):3555-3559
pubmed: 29029165
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Front Pharmacol. 2021 Jan 19;11:579548
pubmed: 33542685
Heart Lung Circ. 2021 Mar;30(3):372-379
pubmed: 32873489
Thromb Haemost. 2014 Mar 3;111(3):392-400
pubmed: 24285296
J Am Coll Cardiol. 2002 Dec 18;40(12):2117-21
pubmed: 12505222
J Intern Med. 2020 Jan;287(1):2-18
pubmed: 31858669
Stroke. 2020 Sep;51(9):e254-e258
pubmed: 32787707
Atherosclerosis. 2021 Mar;320:53-60
pubmed: 33540179
Eur Heart J. 2020 Jan 1;41(1):192-193
pubmed: 31893480
J Neurol Sci. 2021 Feb 15;421:117308
pubmed: 33497950
J Clin Lipidol. 2020 Sep - Oct;14(5):617-618
pubmed: 32653497
Am J Cardiol. 2020 Nov 1;134:153-155
pubmed: 32891399
Curr Atheroscler Rep. 2020 Jul 25;22(9):48
pubmed: 32710255
J Intern Med. 2021 May;289(5):749-751
pubmed: 33222314
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):889-891
pubmed: 32354768
N Engl J Med. 2020 Jun 18;382(25):e102
pubmed: 32356626
Atherosclerosis. 2020 Nov;313:126-136
pubmed: 33045618
Pharmacol Res. 2020 Aug;158:104891
pubmed: 32389859
Atherosclerosis. 2019 Nov;290:138-139
pubmed: 31610884
Stroke. 1988 Sep;19(9):1097-100
pubmed: 3413806
Drugs. 2021 Apr;81(6):685-695
pubmed: 33782908
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504
JAMA Neurol. 2020 Jul 02;:
pubmed: 32614385
Postgrad Med. 2021 Mar;133(2):146-153
pubmed: 32744105

Auteurs

Alpo Vuorio (A)

University of Helsinki, Department of Forensic Medicine, 00014 Helsinki, Finland.
Mehiläinen Airport Health Centre, 01530 Vantaa, Finland.

Markku Kaste (M)

Department of Neurosciences, University of Helsinki, Helsinki, Finland.
Department of Neurology, Helsinki University Hospital, Helsinki, Finland.

Petri T Kovanen (PT)

Wihuri Research Institute, Biomedicum Helsinki 1, 00290 Helsinki, Finland.

Classifications MeSH